Legend Biotech (LEGN) has drawn fresh attention after reporting initial clinical proof of concept data for LB2501, an investigational in vivo CD19/CD20 dual targeting CAR T therapy in relapsed or refractory B cell non Hodgkin lymphoma.
See our latest analysis for Legend Biotech.
Legend Biotech's recent LB2501 update and follow on equity offering of about $226 million come after a sharp shift in sentiment, with the stock posting a 65.74% 3 month share price return but a 1 year total shareholder return that is still down 17.15%. This hints that momentum has picked up recently while longer term holders remain under water.
If LB2501 has you rethinking where growth in healthcare could come from next, it may be worth scanning 39 healthcare AI stocks as a starting point for other ideas.
So with Legend Biotech’s shares climbing 65.7% over 3 months but still showing a 17.2% decline over 1 year, and trading at a steep intrinsic discount, is there genuine upside left, or is the market already pricing in future growth?
Most Popular Narrative: 49.9% Undervalued
Legend Biotech's most followed valuation narrative places fair value at $57.24 per share compared with the last close of $28.69, framing the recent swing in sentiment against a much higher long run target.
Robust innovation pipeline, including next-generation CAR-Ts and in vivo/off-the-shelf cell therapy technologies (e.g., TaVec platform), positions Legend to capitalize on rising demand for advanced, personalized therapies amid secular increases in cancer incidence and sustained healthcare investment, supporting future revenue streams and risk diversification.
Curious what earnings path, revenue build up and margin shift need to happen for that valuation to make sense? The narrative leans on steep compounding, higher profitability and a richer future multiple, all filtered through a 7.31% discount rate.
Result: Fair Value of $57.24 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the bullish Legend Biotech narrative still hinges on CARVYKTI concentration risk and heavy R&D and manufacturing spend, which could delay or blunt profitability.
Find out about the key risks to this Legend Biotech narrative.
Next Steps
If this mix of optimism and caution around Legend Biotech leaves you undecided, it may help to move quickly and test the narrative against your own expectations by reviewing the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Legend Biotech?
If Legend Biotech has sharpened your focus, do not stop here, use the Simply Wall Street Screener to pressure test your portfolio and surface fresh opportunities.
- Target potential upside in quality companies trading below their estimated worth by reviewing the 44 high quality undervalued stocks as a focused hunting ground.
- Prioritise resilience first and cut portfolio stress by scanning the 71 resilient stocks with low risk scores for stocks with lower overall risk profiles.
- Hunt for tomorrow's potential standouts before they are widely followed by checking the screener containing 19 high quality undiscovered gems and seeing which stories catch your eye.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com